The U.S. Food and Drug Administration has cleared a novel continuous glucose monitoring system known as Dexcom G7 15 Day for use in patients aged 18 years and older with diabetes.

The updated continuous glucose monitoring (CGM) system offers up to 15.5 days of wear, making it the longest lasting wearable CGM system currently cleared in the United States. According to a press release from Dexcom, the device also represents one of the most accurate CGM systems available, with a reported mean absolute relative difference of 8.0%.

The novel CGM system maintains the core features of the current G7 platform, including a 12-hour grace period for sensor replacement and a streamlined mobile application with Dexcom Clarity integration for real-time data visualization. The system supports hands-free use by enabling direct connection to compatible Apple Watch devices without requiring a nearby smartphone. It also includes automated activity-, meal-, and medication-logging features designed to enhance patient understanding of glycemic patterns and treatment responses.

The extended wear time is intended to reduce sensor changes and overall device waste, potentially improving adherence and convenience. The sensor remains water resistant and allows for continuous data transmission, even during submersion. The system also supports remote data sharing with caregivers and clinicians and provides customizable alerts for improved discretion.

Dexcom stated that it is working with insulin pump manufacturers to ensure the new CGM system is compatible with automated insulin delivery systems. The company expects Dexcom G7 15 Day to become available in the United States in the second half of 2025. In the interim, clinicians and patients are encouraged to continue using the currently available Dexcom G7 platform, which remains indicated for patients aged 2 years and older.